Oxygen Biotherapeutics, Inc. Expands Board of Directors
14 Dezember 2009 - 2:30PM
PR Newswire (US)
Adds Lt. Gen. Ronald R. Blanck (Ret.) DURHAM, N.C., Dec. 14
/PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC:OXBT)
(BULLETIN BOARD: OXBT) today announced the expansion of the
company's board of directors with the addition of Lt. Gen. Ronald
R. Blanck, DO, U.S. Army (Ret.). Dr. Blanck is chairman of Martin,
Blanck & Associates, a federal health services consulting firm
based in Falls Church, Virginia. With his addition, the company
board now has nine members. Dr. Blanck began his military career in
1968 as a medical officer and battalion surgeon in Vietnam. He
retired 32 years later as a Lieutenant General and Surgeon General
of the U.S. Army and commander of the U.S. Army Medical Command
with more than 46,000 military personnel and 26,000 civilian
employees throughout the world. During his distinguished military
career, Dr. Blanck also served as commander of Walter Reed Medical
Center and the North Atlantic Region Medical Command. After his
military service and prior to joining Martin, Blanck &
Associates, Dr. Blanck served as the president of the University of
North Texas Health Science Center at Fort Worth. As president, Dr.
Blanck headed a growing academic health center that includes the
Texas College of Osteopathic Medicine, Graduate School of
Biomedical Sciences, School of Public Health and School of Health
Professions. "I am very honored that an individual with Ron
Blanck's combination of military and medical credentials is coming
onto our board of directors, especially as we look toward expanding
our efforts in Defense Medicine(TM). As you know, we believe
Oxycyte(TM) has the potential to help reduce the long-term brain
damage to our forces who are blast injury casualties in Iraq and
Afghanistan. His medical expertise and his military contacts should
be helpful in our efforts in this area," said Chris Stern, company
chairman and CEO. "Also, this expansion of the board is part of our
goal to change the board's structure so that it builds out its
majority of independent outside directors, something I believe is
important in view to a move to a major exchange listing," said
Stern. About Oxygen Biotherapeutics, Inc. Oxygen Biotherapeutics,
Inc. is dedicated to commercializing innovative pharmaceuticals and
medical devices in the field of oxygen therapeutics and Defense
Medicine(TM). The company has developed a perfluorocarbon (PFC)
therapeutic oxygen carrier and liquid ventilation product
(Oxycyte(TM)) and has out-licensed an implantable glucose sensor.
These products are based upon core technologies that include
biomedical applications for PFCs as well as medical and industrial
applications for biosensors. Each of the product candidates is
designed with advantages over currently marketed products in major
markets including traumatic brain injury, sickle cell crisis,
trauma, wound care, decompression sickness, acute respiratory
distress syndrome, stroke, myocardial infarction, surgery, diabetes
wounds and ulcers, and cosmetic applications which are being
marketed under the Dermacyte name. More information is available at
http://www.oxybiomed.com/. DATASOURCE: Oxygen Biotherapeutics, Inc.
CONTACT: Abe Wischnia, Abe Wischnia & Associates,
+1-619-795-2345 Web Site: http://www.oxybiomed.com/
Copyright